

Publikační činnost Kliniky hematologie za rok 2018

Publikace in extenso:

Články v časopisech s IF

1. Jurczynszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grząsko N, Robak P, Hus I, Waszczuk-Gajda A, Guzicka-Kazimierczak R, Atilla E, Mele G, Sawicki W¹⁴, Jayabalan DS, Charliński G, Szabo AG, **Hajek R**, Delforge M, Kopacz A, Fantl D, Waage A, Avivi I, Rodzaj M, Leleu X, Richez V, Knopińska-Postuszny W, Masternak A, Yee AJ, Barchnicka A, Druzd-Sitek A, Guerrero-Garcia T, Liu J, Vesole DH, Castillo JJ. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. *Br J Haematol.* 2018 Mar;180(6):831-839. IF 5,67
2. Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, **Hajek R**, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. *Haematologica.* 2018 Feb;103(2):197-211. IF 7,702
3. **Jelínek T**, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Adamová D, Wróbel M, Mikula P, Jarkovský J, Diels J, Gatopoulou X, Veselá Š, Besson H, Brožová L, Ito T, **Hájek R**. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. *Curr Med Res Opin.* 2018 May;34(5):775-783. IF 2,757
4. **Mihalyova J, Jelínek T, Growkova K, Hrdinka M, Simicek M, Hajek R**. Venetoclax: a new wave in hematooncology. *Exp Hematol.* 2018 May;61:10-25 IF 2,436
5. Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Hamouzova M, Belada D, Prochazka V, Pytlik R, Vokurka S, Pirnos J, **Duras J**, Mocikova H, Mayer J, Trneny M. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database. *Ann Hematol.* 2018 Apr;97(4):669-678.
6. **Hájek R**, Jarkovsky J, Maisnar V, Pour L, Špička I, Minařík J, Gregora E, Kessler P, Sýkora M, Fraňková H, Campioni M, DeCosta L, Treur M, Gonzalez-McQuire S, Bouwmeester W. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies. *Clin Lymphoma Myeloma Leuk.* 2018 Jun;18(6):e219-e240. IF 2,494
7. Morrow ME, Morgan MT, Clerici M, **Growkova K**, Yan M, Komander D, Sixma TK, **Simicek M**, Wolberger C. Active site alanine mutations convert deubiquitinases into high-affinity ubiquitin-binding proteins. *EMBO Rep.* 2018 Aug 27. pii: e45680. IF 8,7
8. San-Miguel JF, Echeveste Gutierrez MA, Špicka I, Mateos MV, Song K, Craig MD, Bladé J, **Hájek R**, Chen C, Di Bacco A, Estevam J, Gupta N, Byrne C, Lu V, van de Velde H, Lonial S. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. *Haematologica.* 2018 Sep;103(9):1518-1526. IF 7,702
9. Buske C, Sadullah S, Kastiris E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, **Hájek R**, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia. Treatment and outcome patterns in European patients with

- Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. *Lancet Haematol.* 2018 Jul;5(7):e299-e309. IF 10,698
10. Mina R, Petrucci MT, Corradini P, Spada S, Patriarca F, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, **Hájek R**, Spencer A, Boccadoro M, Bringhen S. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. *Clin Lymphoma Myeloma Leuk.* 2018 Aug;18(8):533-540. IF 2,494
 11. Yong K, Gonzalez-McQuire S, Szabo Z, Schoen P, **Hajek R**. The start of a new wave: Developments in proteasome inhibition in multiple myeloma. *Eur J Haematol.* 2018 Mar 30. doi: 10.1111/ejh.13071. [Epub ahead of print] IF 2,595
 12. Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, **Hajek R**, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. *Leukemia.* 2018 Jul;32(7):1542-1560. IF 10,023
 13. Steiner N, Müller U, **Hajek R**, Sevcikova S, Borjan B, Jöhner K, Göbel G, Pircher A, Günsilius E. The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. *PLoS One.* 2018 Aug 10;13(8):e0202045. IF 2,766
 14. Radocha J, Maisnar V, Pour L, Špička I, Minařík J, Szeligová L, Pavlíček P, Jungová A, Krejčí M, Pika T, Straub J, Brožová L, **Stejskal L**, Heindorfer A, Jindra P, Kessler P, Mikula P, Sýkora M, Wróbel M, Jarkovský J, **Hájek R**. Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. *Cancer Med.* 2018 Aug;7(8):4132-4145. IF 3,202
 15. Steiner N, **Hajek R**, Sevcikova S, Borjan B, Untergasser G, Göbel G, Günsilius E. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma. *Anticancer Res.* 2018 Sep;38(9):5087-5092. IF 1,865
 16. Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, **Hájek R**, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M. Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. *JAMA Oncol.* 2018 Oct 1;4(10):1389-1397. IF 20,871
 17. Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastiris E, van de Donk N, Gay F, Hegenbart U, **Hajek R**, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. *Leukemia.* 2018 Sep;32(9):1883-1898. IF 10,023
 18. Jurczynszyn A, Davila J, Kortüm KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wiśniewska-Piąty K, Waszczuk-Gajda A, Crusoe E, **Hajek R**, Robak P, Rażny M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. *Leuk Lymphoma.* 2018 Jul 22:1-6. IF 2,644
 19. Jurczynszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząsko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, **Hajek R**, Delforge

- M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. *Leuk Lymphoma*. 2018 Jul 2:1-6. IF 2,644
20. **Chyra Kufova Z, Sevcikova T**, Januska J, Vojta P, Boday A, Vanickova P, Filipova J, **Growkova K, Jelinek T**, Hajduch M, **Hajek R**. Newly designed 11-gene panel reveals first case of hereditary amyloidosis captured by massive parallel sequencing. *J Clin Pathol*. 2018 Aug;71(8):687-694. IF 2,894
 21. Prochazka V, Jonszta T, Czerny D, Krajca J, Roubec M, Macak J, Kovar P, Kovarova P, Pulcer M, Zoubkova R, Lochman I, Svachova V, Pavliska L, Vrtkova A, Kasprak D, **Gumulec J**, Weisel JW. The Role of von Willebrand Factor, ADAMTS13, and Cerebral Artery Thrombus Composition in Patient Outcome Following Mechanical Thrombectomy for Acute Ischemic Stroke. *Med Sci Monit*. 2018 Jun 11;24:3929-3945. IF 1,894
 22. Belada D, Prochazka V, Janikova A, Campr V, Blahovcova P, Pytlik R, Sykorova A, Klener P, Benesova K, Pirnos J, **Duras J**, Mocikova H, Trneny M. The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group. *Leuk Res*. 2018 Oct;73:29-38. IF 2,319
 23. Richardson PG, San Miguel JF, Moreau P, **Hajek R**, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. *Blood Cancer J*. 2018 Nov 9;8(11):109. IF 6,122
 24. **Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R**. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. *Immunology*. 2017 Nov;152(3):357-371. IF 3.358
 25. Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschmidt H, **Hajek R**, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. *Blood Cancer J*. 2018 Nov 23;8(12):123. IF 6,122
 26. Königova N, Skoumalova I, Onderkova J, Ambruzova Z, Sotkowski T, **Koristek Z**, Maluskova A, Raida L, Mrazek F. HLA-B gene somatic insertion/deletion mutations in patients with acute myelogenous leukaemia. *Int J Immunogenet*. 2018 Dec;45(6):323-328. IF 1,0
 27. Jelinek T, Paiva B, Hajek R. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma. *Front Immunol*. 2018 Nov 16;9:2431. IF 5,511

Články v recenzovaných časopisech

1. Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, **Hajek R**, Groarke J, Lyon AR, Batty GN, Ro S, Huang M, Iskander KS, Lenihan D. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. *Blood Adv*. 2018 Jul 10;2(13):1633-1644.
2. **Zuchnická J, Fečková Mihályová J, Ištvaníková L**. Obinutuzumab v první linii léčby chronické lymfocytární leukemie – zkušenosti u klinické praxe. *Remedia* 2018;4(28):377-381.
3. **Hájek R**, Krejčí M, Maisnar V, **Jelínek T**, et al. Diagnostika a léčba mnohočetného myelomu, Doporučení vypracované Českou myelomovou skupinou, Myelomovou sekcí České hematologické společnosti a Slovenskou Myelómovou Spoločnosťou pro diagnostiku a léčbu mnohočetného myelomu. *Transfúze Hematol. dnes* 2018; Supplementum1 24: 1-157.
4. Almasi M, Besse L, Brozova L, Jarkovsky J, Bezdekova R, Pour L, Minarik J, Kessler P, Pavlíček P, Roziakova L, Penka M, **Hájek R**, Vasku A, Sevcikova S. Selected Genetic Polymorphisms

- Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients. *Klin Onkol.* 2018 Spring;31(3):213-229.
5. Adamusová, L., Kořístek Z., Smejkalová J., Navrátil M., Grebeníček L., Tvrdá I., Michalíková M., **Hájek R.** Automatizované promývání transplantátů krvetvorných buněk pro autologní použití. *Transfúze a hematologie dnes* 2018;2(24):115-122.
 6. Veronika Švachová, **Zdeněk Kořístek**, Přemysl Falt, Ivo Lochman. QuantiFERON Monitor (QFM) a testy z plné krve pro posuzování buněčné imunity. *Alergie* 2018;20(2): 91-97.
 7. **Kořístek, Zdeněk.** Komentář ke studii. *Farmakoterapie* 2018;3(14):474-475.
 8. **Gumulec J.** Hematologie na JIP/ARO, management antikoagulační prevence v krizových situacích. *TRANSFUZE HEMATOL. DNES 24, SUPPLEMENTUM 2/a; 2018, s. 124*

Články v ostatních časopisech

1. **Jelínek T, Mihályová J, Hájek R.** CD38 cílená léčba u mnohočetného myelomu. *Vnitř Lék* 2018; 64(10): 939-948.

Přednášky:

Přednášky (zahraniční konference)

1. **Hájek R.** Immunomodulation & Immunotherapy in MM. 8. Konferencja CURRENT & FUTURE PERSPECTIVES OF MM TREATMENT, Warsaw, Poland, 2/2018
2. **Hájek R.** The role of minimal residual disease in MM in 2018. Hematology Chronic Dialogues, Cluj-Napoca, Romania, 3/2018
3. **Hájek R.** Practical management of daratumumab in patients with MM in Czech Republic. Hematology Chronic Dialogues, Cluj-Napoca, Romania, 3/2018
4. **Hájek R.** Multiple myeloma-best practices from Czech Republic. educational event Treatment of lymphoproliferative diseases an update, Trakošćan, Croatia, 3/2018
5. **Hájek R.** The role of autologous transplantation in multiple myeloma. Conference „Progress in transplantology, haematology and cell therapies”, Szczecin, Poland, 5/2018
6. **Hájek R.** LÉČEBNÁ STRATEGIE MNOHOČETNÉHO MYELOMU & GUIDELINES 2018. Myelómové fórum 2018, Bratislava, Slovak Republic, 5/2018
7. **Hájek R.** Multiple Myeloma - A Quick Reflection on the Fast Progress. III International Conference on Clinical and Experimental Hematology, Kazimierz Dolny, Poland, 5/2018
8. **Hájek R.** Chair of the EHA-ISLH Laboratory Diagnosis Workshop Symposium on “MRD diagnostics in multiple myeloma trials”. 23rd Congress of the European Hematology Association (EHA), Stockholm, Sweden, 6/2018
9. **Hájek R.** CEE experience in advancing new technologies to MM patients. CEE Health Innovation Forum, Warsaw, Poland, 6/2018
10. **Hájek R.** Multiple Myeloma - A Quick Reflection on the Fast Progress. IX. Bratislavské hematologické a transfúziologické dny, Bratislava, 10/2018
11. **Kořístek Z.** Mobilizácia krvotvorných buniek pri mnohopočetnom myelóme. IX. Bratislavské hematologické a transfúziologické dny, Bratislava, 10/2018

12. **Hájek R.** Registry of monoclonal gammopathies (RMG). NEE Multiple Myeloma Expert Forum, Bucharest, 11/2018
13. **Hájek R.** Practical aspects of MM treatment – sequencing, duration or treatment. NEE Multiple Myeloma Expert Forum, Bucharest, 11/2018
14. **Hájek R.** Multiple Myeloma - A Quick Reflection on the Fast Progress. Scientific Symposium “Paraproteinemic hemoblastosis”, Novosibirsk, 11/2018

Přednášky (tuzemská konference)

1. **Zuchnická Jana.** MDS - revize WHO klasifikace 2016. XXIV. Pařízkovy dny, Ostrava, 3/2018
2. **Zuchnická Jana.** Kazuistika CLL. XXIV. Pařízkovy dny, Ostrava, 3/2018
3. **Jelínek Tomáš.** Overview of cell therapies in multiple myeloma and acute myeloid leukemia, Cell therapy workshop, 2/2018, Ostrava
4. **J. Gumulec, V. Procházka, I. Lochman, D. Kaspřák.** Expected and less expected roles of von Willebrand factor in etiopathogenesis (and treatment) of ischemic stroke. XXIV. Pařízkovy dny, Ostrava, 3/2018
5. **Z. Kořístek, D. Kaspřák, J. Gumulec.** Kazuistika dospělého pacienta s atypickým hemolyticko-uremickým syndromem. XXIV. Pařízkovy dny, Ostrava, 3/2018
6. **L. Ištvániková.** Vlasotobuněčná leukemie s náhlou ztrátou hybnosti. XXIV. Pařízkovy dny, Ostrava, 3/2018
7. **M. Zulák.** Kazuistika pacienta s trombotickou mikroangiopatií. XXIV. Pařízkovy dny, Ostrava, 3/2018
8. **S. Szoradová.** Kazuistika PAT negativní AIHA asociovaná s CMV. XXIV. Pařízkovy dny, Ostrava, 3/2018
9. **Stejskal L.** Polycythemia vera - Novinky z kongresu ASH 2017. XXIV. Pařízkovy dny, Ostrava, 3/2018
10. **M. Zátoková.** Whole exome profiling of minimal residual disease in multiple myeloma. XXIV. Pařízkovy dny, Ostrava, 3/2018
11. **D. Kaspřák.** Genomic studies in thrombotic microangiopathies. XXIV. Pařízkovy dny, Ostrava, 3/2018
12. **P. Richterová.** Kazuistika. XXIV. Pařízkovy dny, Ostrava, 3/2018
13. **R. Hájek.** Novinky z kongresu ASH. XXIV. Pařízkovy dny, Ostrava, 3/2018
14. **T. Jelínek, H. Plonková.** Kazuistika pacienta s mnohočetným myelomem: focus na autologní transplantaci a první relaps. XXIV. Pařízkovy dny, Ostrava, 3/2018
15. **Zuchnická Jana.** Chronická lymfocytární leukémie – kdy a jakými léky léčíme. REGIONÁLNÍ SETKÁNÍ PACIENTŮ S CML A CLL A JEJICH RODINNÝCH PŘÍSLUŠNÍKŮ, Ostrava, 3/2018 .
16. **Stejskal Lukáš.** Interakce léků při léčbě CML. REGIONÁLNÍ SETKÁNÍ PACIENTŮ S CML A CLL A JEJICH RODINNÝCH PŘÍSLUŠNÍKŮ, Ostrava, 3/2018 .
17. **Stejskal Lukáš.** Riziko infekčních komplikací u pacientů s myelodysplastickým syndromem a jak jim předcházet. 1. regionální setkání pacientů s MDS a jejich rodinných příslušníků v Ostravě, 3/2018.
18. **Kateřina Growková et al.** Mutace v 19S regulační podjednotce proteasomu představují nový mechanismus rezistence na proteasomové inhibitory u pacientů s mnohočetným myelomem. XVI. národní workshop mnohočetný myelom a Roční setkání CMG, Mikulov, 4/2018
19. **Jelínek Tomáš.** Daratumumab a RMG, XXIV. Pařízkovy dny, Ostrava, 3/2018

20. **Jelínek Tomáš.** Monoterapie daratumumabem u silně předléčené pacientky s mnohočetným myelomem, XVI. národní workshop mnohočetný myelom a Roční setkání CMG, Mikulov, 4/2018
21. **Martina Zátopková,** Tereza Sevcikova, Zuzana Kufova, et al. Minimal residual disease in multiple myeloma from genomic point of view. XIII. Multiple myeloma workshop, Brno, 10/2018
22. **Duraš J.** Kazuistika nemocného s DLBCL. Plenární zasedání KLS 2018, Praha, 2018
23. **Adamusová L.** Mobilizace pomocí cytosinarabinosidu je u pacientů s mnohočetným myelomem bezpečná a výrazně účinnější než použití cyklofosfamidu. 1. český hematologický a transfuziologický sjezd Praha, 9/2018
24. **Roman Hájek.** Understanding where we are going in the field of monoclonal gammopathies. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 11/2018, Ostrava
25. **Michal Kaščík.** What are specific diagnostic tools for IgM MGUS and MorbusWaldenström? "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 11/2018, Ostrava
26. **Roman Hájek.** CRAB & high risk SMM. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 11/2018, Ostrava
27. **Roman Hájek.** Principles of modern treatment of multiple myeloma - first targets, sequential and long-term strategy. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 11/2018, Ostrava
28. **Roman Hájek.** Principles of modern treatment of amyloidosis. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 11/2018, Ostrava
29. **Michal Kaščík.** Principles of modern treatment of MorbusWaldenström. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 11/2018, Ostrava
30. **Tomáš Jelínek.** Immunotherapy in multiple myeloma. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 11/2018, Ostrava
31. **Roman Hájek.** Frontline treatment of multiple myeloma. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 11/2018, Ostrava
32. **Tomáš Jelínek.** Case study discussion: Decision-making in frontline treatment. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 11/2018, Ostrava
33. **Tomáš Jelínek.** Detection of MRD by flow cytometry in multiple myeloma. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 11/2018, Ostrava
34. **Roman Hájek.** Treatment strategy in RRMM. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 11/2018, Ostrava
35. **Tomáš Jelínek.** Utility of multiparameter flow cytometry in plasma cell disorders. "Understanding of Modern Haematology: Focus on Monoclonal Gammopathies", 11/2018, Ostrava
36. **Jelínek Tomáš.** Update on selinexor in multiple myeloma, CMG farmako-ekonomický seminář, 11/2018, Brno
37. **Jelínek Tomáš.** Daratumumab a RMG, CMG farmako-ekonomický seminář, 11/2018, Brno
38. **Gumulec Jaromír.** Těžký HELLP syndrom a postpartální trombotické mikroangiopatické syndromy: analýza výsledků 9 žen z FN Ostrava na kongresu Koagulace a krvácení 2018, Hluboká nad Vltavou
39. **Gumulec Jaromír.** Splenektomie u hematologických pacientů: riziko infekčních komplikací na celostátním vakcinologickém kongresu XIV. Hradecké vakcinologické dny, Hradec Králové
40. **Gumulec Jaromír.** Laboratorní diagnostika a diferenciální diagnostika u pacientů s podezřením na akutní ataku TMA na I. Českém hematologickém a transfuziologickém sjezdu, Praha

41. **Gumulec Jaromír.** Hematologie na JIP/ARO, management antikoagulační prevence v krizových situacích na I. Českém hematologickém a transfuziologickém sjezdu, Praha
42. **Gumulec Jaromír.** Soustředěná péče zlepšuje prognózu žen s těžkým HELLP syndromem a s postpartálním trombotickým mikroangiopatickým syndromem na I. Českém hematologickém a transfuziologickém sjezdu, Praha
43. **Gumulec Jaromír.** Hemolytické syndromy u kriticky nemocných pacientů na Slovensko České konferenci o hemostáze a trombóze, Martin
44. **Gumulec Jaromír.** Von Willebrand "multitasking" factor na Slovensko České konferenci o hemostáze a trombóze, Martin
45. **Gumulec Jaromír.** Trombotické mikroangiopatie v peripartálním období na konferenci Společnosti perinatologie a fetomaternální medicíny, Mikulov
46. **Gumulec Jaromír.** Role hematologa v reprodukční medicíně na Jarním hematologickém sympoziu regionu jižní Morava a Vysočina, Třebíč
47. **Gumulec Jaromír.** Expected and less expected roles of vWF in ethiopatho-genesis (and treatment) of ischemic stroke na Pařížkových dnech, Ostrava
48. **Gumulec Jaromír.** Hemolytické syndromy u kriticky nemocných pacientů na Colours of Sepsis, Ostrava
49. **Gumulec Jaromír.** Prevence tromboembolické nemoci u chirurgického pacienta na sympoziu EARLY RECOVERY AFTER SURGERY na Colours of Sepsis, Ostrava

Postery:

Postery (zahraniční konference)

1. **Zuzana Kufova Chyra, Tereza Sevcikova, Petr Vojta, Jana Filipova, Katerina Growkova, Martin Stork, Ludek Pour, Paweł Robak, Jakub Debski, Wieslaw Wiktor-Jedrzejczak, Anna Waszczuk-Gajda, Alexandra Jungova, Sebastian Grosicki, Agnieszka Barchnicka, Artur Jurczynsyn, Michal Simicek, Marian Hajduch, Roman Hajek.** Immunoglobulin light chain amyloidosis mutational landscape revealed by exome sequencing. The XVIth International Symposium on Amyloidosis, Kumamoto, Japan, 3/ 2018
2. **Zatopkova M., Stracquadanio G., Sevcikova T., Vojta P., Simicek M., Growkova K., Chyra Kufova Z., Filipova J., Jelinek T., Rihova L., Bezdekova R., Smejkalova J., Hajduch M., , Minarik J., Jungova A., Maisnar V., Pour L., Kryukov F., Hajek R.** A PRELIMINARY ANALYSIS OF SOMATIC EXOME MUTATIONS OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA. 1 st European Myeloma Network Meeting, Turin, Italy, 4/2018
3. Jiri Minarik, **Roman Hajek**, Alexandra Jungova, Martin Mistrik, Tomas Pika, Evzen Gregora, Jakub Radocha, Jan Straub, Ludek Pour, Marek Wrobel, Lucie Brozova, Jaroslav Bacovsky, Petra Krhovska, **Katarina Hradska**, Pavel Jindra, Petr Pavlicek, Katerina Machalkova, Ivan Spicka, Martin Stork, **Tomas Jelinek, Hana Plonkova**, Vlastimil Scudla, Vladimir Maisnar. IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE FOR RELAPSED AND REFRACTORY MULTIPLE MYELOMA – DATA FROM THE CZECH REGISTRY OF MONOCLONAL GAMMOPATHIES. 23rd Congress of the European Hematology Association (EHA), Stockholm, Sweden, 6/2018
4. **Roman Hájek**, Michel Delforge, Marc Raab, Andrew Briggs, Marco Campioni, Lucy DeCosta, Zsolt Szabo, Sonja Kroep, Walter Bouwmeester, Sebastian Gonzalez-Mcquire. A NOVEL RISK-STRATIFICATION ALGORITHM FOR RELAPSED MULTIPLE MYELOMA (RMM): ASSESSMENT OF PERFORMANCE AND VALIDATION USING REAL-WORLD PATIENT DATA FROM FRANCE, GERMANY AND THE UNITED KINGDOM. 23rd Congress of the European Hematology Association (EHA), Stockholm, Sweden, 6/2018

5. Santiago Barrio, **Michal Šimíček**, Matteo DaVia, **Katerina Growkova**, Max Bittrich, Hermann Einsele, **Roman Hajek**, K. Martin Kortüm. Mutations In 19s Proteasome Subunits Represent A Novel Mechanism Of Acquired Resistance To Proteasome Inhibitors In Multiple Myeloma Patients. 23rd Congress of the European Hematology Association (EHA), Stockholm, Sweden, 6/2018
6. **Zatopkova M.**, Stracquadanio G., **Sevcikova T.**, **Growkova K.**, **Chyra Kufova Z.**, **Filipova J.**, **Jelinek T.**, Rihova L., Bezdekova R., **Šimíček M.**, **Smejkalova J.**, Minarik J., Jungova A., Maisnar V., Pour L., Mistrik, Kryukov F., **Hajek R.** Whole exome sequencing of residual disease in multiple myeloma: searching for novel therapeutic targets. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
7. Minarik J, Krhovska P, **Jelinek T**, Jungova A, Mistrik M, Pika T, Gregora E, Maisnar V, Straub J, Pour L, Brozova L, Bacovsky J, **Plonkova H**, Jindra P, Pavlicek P, Radocha J, Spicka I, Stork M, Scudla V, **Hajek R.** Treatment of relapsed and refractory multiple myeloma with fully oral triplet IRD (ixazomib, lenalidomide and dexamethasone) is safe and with significant therapeutic outcomes. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
8. Juan-Jose Garces, **Michal Šimíček**, Marco Vicari, Lucie Brozova, Leire Burgos, Renata Bezdekova, Diego Alignani, Maria-José Calasanz, **Kateřina Growková**, Ludek Pour, Rafel Rios, Joaquin Martinez-Lopez, Pamela Millacoy, Luis Palomera, Rafel del Orbe, Sonia Garate, Laura Blanco, Patricia Maiso, **Zuzana Chyra**, **Alexander Vdovin**, **Tomas Jelinek**, Cirino Botta, Halima El Omri, Jonathan Keats, Xabier Agirre, Felipe Prosper, **Roman Hajek**, Jesús San Miguel, Bruno Paiva. Profiling Peripheral Blood (PB) Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): A New Model to Understand Disease Dissemination. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
9. Radocha J, **Hajek R**, Brozova L, Pour L, Spicka I, Minarik J, **Jelinek T et al.** Treatment Outcomes of Real Life Elderly Multiple Myeloma Patients: A Analysis from Registry of Monoclonal Gammopathies (RMG). *Blood* 2018; **132**: 2019–2019.
10. Stork M, Sevcikova S, Krejci M, Adam Z, Sandecka V, Maisnar V, **Jelinek T et al.** Risk Factors Associated with Development of Extramedullary Disease in Multiple Myeloma. *Blood* 2018; **132**: 5596–5596.
11. Francesca Gay, Valeria Magarotto, MD, Maria Teresa Petrucci, Francesco Di Raimondo, Luděk Pour, Tommaso Caravita, Vlastimil Scudla, Anna Maria Cafro, Anna Marina Liberati, Stefano Spada, Maisnar Vladimir, Norbert Pescosta, Roberto Ria, Massimo Offidani, Sara Bringhen, Annalisa Bernardini, Francesca Patriarca, Paolo Corradini, Roberto Fo, Nicola Cascavilla, Lucio Catalano, Andrew Spencer, **Roman Hajek**, Mario Boccadoro, MD and Antonio Palumbo. Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial.
12. Roberto Mina, Alessandra Larocca, Massimo Offidani, Sara Bringhen, Tommaso Caravita, Valeria Magarotto, MD, Lucia Pantani, MD, Francesco Di Raimondo, Alberto Bosi, Iolanda D. Vincelli, Paola Tacchetti, MD, Gianluca Gaidano, Sonia Grandi, Caterina Musolino, Chiara Cerrato, Ludek Pour, Monica Astolfi, Giuseppe Rossi, MD, Fausto Rossini, Maria T. Petrucci, Roberto Ria, Annalisa Pezzi, PhD, **Roman Hajek**, Michele Cavo, Andrew Spencer, Mario Boccadoro, MD and Antonio Palumbo. Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
13. Christian Buske, Shalal Sadullah, FRCP, FRCPath, Efsthatis Kastitis, MD, Giulia Benevolo, MD, Ramon Garcia-Sanz, MD, Lukasz Bolkun, MD, PhD, Xavier Leleu, MD, PhD, Wolfgang Willenbacher, MD, **Roman Hajek**, MD, Ellen van der Spek, MD, PhD, Mei Cheng, PhD, Thorsten Graef, MD, PhD and Meletios A. Dimopoulos, MD3 Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's

- Macroglobulinemia. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
14. Jakub Radocha, MD, PhD, Ludek Pour, MD, PhD, Ivan Spicka, MD, PhD, Vlastimil Scudla, MD, PhD, Evzen Gregora, MD, Hana Frankova, MD, **Roman Hajek**, MD, Miroslava Schutzova, MD, Michal Sykora, MD, Petr Kessler, MD, Dagmar Adamova, MD, Marek Wrobel, MD, Lenka Sedlarikova, MSc, Sabina Sevcikova, RNDr, PhD, Daniel Horinek, MSc, Jana Pelcova, Bc, Lucie Brozova, Mgr, Jiri Jarkovsky, MSc, PhD and Vladimir Maisnar, MD, PhD. Registry of Monoclonal Gammopathies (RMG) in the Czech Republic. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
 15. Wee-Joo Chng, Hartmut Goldschmidt, Meletios A. Dimopoulos, Philippe Moreau, Douglas Joshua, Antonio Palumbo, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD, Laura Rosinol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng and **Roman Hajek**. Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
 16. Philippe Moreau, Douglas Joshua, Wee-Joo Chng, Antonio Palumbo, Hartmut Goldschmidt, **Roman Hajek**, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD, Laura Rosinol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng and Meletios Dimopoulos. Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
 17. H. Avet-Loiseau, MD, Rafael Fonseca, MD, David S Siegel, MD, PhD, Meletios A. Dimopoulos, Ivan Spicka, Tamas Masszi, **Roman Hajek**, Laura Rosinol, Vesselina Goranova-Marinova, Georgi Mihaylov, Vladimir Maisnar, Maria-Victoria Mateos, Michael Wang, MD, Ruben Niesvizky, MD, Albert Oriol, Andrzej Jakubowiak, MD, PhD, Jiri Minarik, Antonio Palumbo, William Bensinger, MD, Vishal Kukreti, Dina Ben-Yehuda, Margaret Tonda, Mihaela Obreja and Philippe Moreau. Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
 18. Antonio Palumbo, Meletios A. Dimopoulos, Philippe Moreau, Wee-Joo Chng, Hartmut Goldschmidt, **Roman Hajek**, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD, Laura Rosinol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng and Douglas Joshua. Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
 19. Chiara Cerrato, Francesca Gay, Maria Teresa Petrucci, Pellegrino Musto, Gianluca Gaidano, Massimo Offidani, Tommasina Guglielmelli, Marco Salvini, Francesca Patriarca, Elena Ponticelli, Gianpietro Semenzato, Francesco Di Raimondo, Roberto Mina, Nicola Cascavilla, Dina Ben Yehuda, Daniela Oddolo, Paolo Corradini, Lucio Catalano, Paolo Di Bartolomeo, **Roman Hajek**, Andrew Spencer, Mario Boccadoro, MD and Antonio Palumbo. Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
 20. Stuart D Russell, Alexander Lyon, Daniel J. Lenihan, MD, Philippe Moreau, Douglas Joshua, Wee-Joo Chng, Antonio Palumbo, Hartmut Goldschmidt, **Roman Hajek**, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD PhD, Laura Rosinol, MD PhD, Aleksandr

Suvorov, Gianluca Gaidano, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng and Meletios A. Dimopoulos. Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018

Postery (tuzemská konference)

1. **Kaspřák David, Kořístek Zdeněk, Navrátil Milan, Šimetka Ondřej, Káňová Marcela, Richterová Petra a Gumulec Jaromír.** Vybrané případy trombotické mikroangiopatie z klinické praxe KHO FNO. XXIV. Pařízkovy dny, Ostrava, 3/2018
2. **Kaspřák David, Kořístek Zdeněk, Šimetka Ondřej, Šuláková Terezie, Zaoral Tomáš a Gumulec Jaromír.** Centrum pro trombotické mikroangiopatie Ostrava. XXIV. Pařízkovy dny, Ostrava, 3/2018
3. **Zuzana Kufova, Katerina Growkova, Petr Vojta, Jana Filipova, Michal Simicek, Tomas Jelinek, Martina Zatopkova, Sebastian Grosicki, Aneta Mikulasova, Marian Hajduch, Ludek Pour, Martin Stork, Tereza Sevcikova and Roman Hajek.** Whole Exome Sequencing of Plasma Cells precancerous MGUS and Malignant AL Amyloidosis Reveals Small Number of Shared Mutated Genes. XXIV. Pařízkovy dny, Ostrava, 3/2018
4. **Zuzana Kufova, Tereza Sevcikova, Petr Vojta, Jana Filipova, Katerina Growkova, Sebastian Grosicki, Fedor Kryukov, Roman Hajek.** Exome sequencing of AL amyloidosis reveals recurrently mutated genes. XXIV. Pařízkovy dny, Ostrava, 3/2018
5. **Lucie Brozova, Fedor Kryukov, Jana Filipova, Tereza Sevcikova, Zuzana Kufova, Katerina Growkova, Elena Kryukova, Jan Smetana, Pavel Nemeč, Jiri Jarkovsky, Roman Hajek, Michal Simicek.** Novel Approach to Study Relationship Between Copy Number Variation and Gene Expression in Multiple Myeloma. XXIV. Pařízkovy dny, Ostrava, 3/2018
6. **Tomas Jelinek, Aintzane Zabaleta, Cristina Perez, Daniel Ajona, Diego Alignani, Idoia Rodriguez, Sonia Garate, Sarai Sarvide, Marta Lasa, Patricia Maiso, Felipe Prosper, Roman Hajek, Jesus F. San Miguel and Bruno Paiva.** Pre-Clinical Efficacy of the Anti-CD38 Monoclonal Antibody (mAb) Isatuximab in Acute Myeloid Leukemia (AML). XXIV. Pařízkovy dny, Ostrava, 3/2018
7. **Popková T, Jelínek T, Plonková H, Szeligová L, Benková K, Kořístek Z, Zuchnická J, Navrátil M, Ďuraš J, Gumulec J, Growková K, Šimíček M, Hájek R.** První zkušenosti s venetoclaxem u pacientů s relabovaným/refrakterním mnohočetným myelomem. 1. český hematologický a transfuziologický sjezd Praha, 9/2018
8. **H. Plonková, T. Jelínek, L. Szeligová, T. Popková, Z. Kořístek, J. Zuchnická, M. Navrátil, J. Ďuraš, J. Gumulec, R. Hájek.** Výsledky léčby pacientů s mnohočetným myelomem na KHO FN Ostrava za rok 2017. 1. český hematologický a transfuziologický sjezd Praha, 9/2018
9. **Adamusová Lucie, Jelínek Tomáš, Hájek Roman, Kořístek Zdeněk.** Mobilizace pomocí cytarabinu – účinná alternativa k cyklofosfamidu u pacientů s mnohočetným myelomem, XXXII. Olomoucké hematologické dny, 5/2018

Abstrakta:

1. **Zátopková M, Sevcikova T, Kufova Z, Growkova K, Filipova J, Jelinek T** et al. Whole Exome Sequencing of Residual Disease in Multiple Myeloma: Searching for Novel Therapeutic Targets. *Blood* 2018; 132: 3175–3175.
2. Minarik J, Krhovska P, **Jelinek T**, Jungova A, Mistrik M, Pika T et al. Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes. *Blood* 2018; 132: 1959–1959.
3. Garcés JJ, **Šimíček M**, Vicari M, Brozova L, Burgos L, Bezděková R et al. Transcriptomic Profiling of Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): A New Model to Understand Disease Dissemination. *Blood* 2018; 132: 245–245.
4. Jiri Minarik, **Roman Hajek**, Alexandra Jungova, Martin Mistrik, Tomas Pika, Evzen Gregora, Jakub Radocha, Jan Straub, Ludek Pour, Marek Wrobel, Lucie Brozova, Jaroslav Bacovsky, Petra Krhovska, Katarina Hradska, Pavel Jindra, Petr Pavlicek, Katerina Machalkova, Ivan Spicka, Martin Stork, **Tomas Jelinek, Hana Plonkova**, Vlastimil Scudla, Vladimir Maisnar. Ixazomib, lenalidomide and dexamethasone for relapsed and refractory multiple myeloma – data from the Czech registry of monoclonal gammopathies, EHA, 2018
5. **Adamusová Lucie, Jelínek Tomáš, Šimíček Michal, Navrátil Milan, Kaščák Michal, Plonková Hana, Mihályová Jana, Ďuraš Juraj, Tvrďá Ivana, Hájek Roman, Kořístek Zdeněk**. Mobilizace pomocí cytosinarabinosidu je u pacientů s mnohočetným myelomem bezpečná a výrazně účinnější než použití cyklofosfamidu. 1. český hematologický a transfuziologický sjezd Praha, 9/2018
6. **Roman Hájek**, Michel Delforge, Marc Raab, Andrew Briggs, Marco Campioni, Lucy DeCosta, Zsolt Szabo, Sonja Kroep, Walter Bouwmeester, Sebastian Gonzalez-Mcquire. A NOVEL RISK-STRATIFICATION ALGORITHM FOR RELAPSED MULTIPLE MYELOMA (RMM): ASSESSMENT OF PERFORMANCE AND VALIDATION USING REAL-WORLD PATIENT DATA FROM FRANCE, GERMANY AND THE UNITED KINGDOM. 23rd Congress of the European Hematology Association (EHA), Stockholm, Sweden, 6/2018
7. **Zatopkova M.**, Stracquadanio G., **Sevcikova T.**, Vojta P., **Simicek M.**, **Growkova K.**, **Chyra Kufova Z.**, **Filipova J.**, **Jelinek T.**, Rihova L., Bezedkova R., **Smejkalova J.**, Hajduch M., Minarik J., Jungova A., Maisnar V., Pour L., Kryukov F., **Hajek R.** A PRELIMINARY ANALYSIS OF SOMATIC EXOME MUTATIONS OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA. 1 st European Myeloma Network Meeting, Turin, Italy, 4/2018
8. **Lucie Adamusová, Tomáš Jelínek, Michal Šimíček, Milan Navrátil, Michal Kaščák, Hana Plonková, Jana Mihályová, Juraj Ďuraš, Ivana Tvrďá, Zdeněk Kořístek, Roman Hájek**. CYTARABINE IS MORE EFFECTIVE THAN CYCLOPHOSPHAMIDE AS A STEM CELL MOBILIZATION REGIMEN IN MULTIPLE MYELOMA. 23rd Congress of the European Hematology Association (EHA), Stockholm, Sweden, 6/2018
9. **Ďuraš J.** Predikce celkového přežití u pacientů s folikulárním lymfomem vysokého věku: srovnání 2 prognostických modelů. Český hematologický sjezd 2018
10. Otahal P, **Ďuraš J** et al.: The Fate of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL), *Blood* 2018 132:5413
11. Francesca Gay, Valeria Magarotto, MD, Maria Teresa Petrucci, Francesco Di Raimondo, Luděk Pour, Tommaso Caravita, Vlastimil Scudla, Anna Maria Cafro, Anna Marina Liberati, Stefano Spada, Maisnar Vladimir, Norbert Pescosta, Roberto Ria, Massimo Offidani, Sara Bringhen, Annalisa Bernardini, Francesca Patriarca, Paolo Corradini, Roberto Fo, Nicola Cascavilla, Lucio Catalano, Andrew Spencer, **Roman Hajek**, Mario Boccadoro, MD and Antonio Palumbo. Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
12. Roberto Mina, Alessandra Larocca, Massimo Offidani, Sara Bringhen, Tommaso Caravita, Valeria Magarotto, MD, Lucia Pantani, MD, Francesco Di Raimondo, Alberto Bosi, Iolanda D. Vincelli,

- Paola Tacchetti, MD, Gianluca Gaidano, Sonia Grandi, Caterina Musolino, Chiara Cerrato, Ludek Pour, Monica Astolfi, Giuseppe Rossi, MD, Fausto Rossini, Maria T. Petrucci, Roberto Ria, Annalisa Pezzi, PhD, **Roman Hajek**, Michele Cavo, Andrew Spencer, Mario Boccadoro, MD and Antonio Palumbo. Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
13. Christian Buske, Shalal Sadullah, FRCP, FRCPath, Efsthathios Kastritis, MD, Giulia Benevolo, MD, Ramon Garcia-Sanz, MD, Lukasz Bolkun, MD, PhD, Xavier Leleu, MD, PhD, Wolfgang Willenbacher, MD, **Roman Hajek**, MD, Ellen van der Spek, MD, PhD, Mei Cheng, PhD, Thorsten Graef, MD, PhD and Meletios A. Dimopoulos, MD3 Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
 14. Jakub Radocha, MD, PhD, Ludek Pour, MD, PhD, Ivan Spicka, MD, PhD, Vlastimil Scudla, MD, PhD, Evzen Gregora, MD, Hana Frankova, MD, **Roman Hajek**, MD, Miroslava Schutzova, MD, Michal Sykora, MD, Petr Kessler, MD, Dagmar Adamova, MD, Marek Wrobel, MD, Lenka Sedlarikova, MSc, Sabina Sevcikova, RNDr, PhD, Daniel Horinek, MSc, Jana Pelcova, Bc, Lucie Brozova, Mgr, Jiri Jarkovsky, MSc, PhD and Vladimir Maisnar, MD, PhD. Registry of Monoclonal Gammopathies (RMG) in the Czech Republic. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
 15. Wee-Joo Chng, Hartmut Goldschmidt, Meletios A. Dimopoulos, Philippe Moreau, Douglas Joshua, Antonio Palumbo, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD, Laura Rosinol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng and **Roman Hajek**. Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
 16. Philippe Moreau, Douglas Joshua, Wee-Joo Chng, Antonio Palumbo, Hartmut Goldschmidt, **Roman Hajek**, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD, Laura Rosinol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng and Meletios Dimopoulos. Impact of Prior Treatment on Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in a Subgroup Analysis of the Phase 3 Endeavor Study (NCT01568866). 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
 17. H. Avet-Loiseau, MD, Rafael Fonseca, MD, David S Siegel, MD, PhD, Meletios A. Dimopoulos, Ivan Spicka, Tamas Masszi, **Roman Hajek**, Laura Rosinol, Vesselina Goranova-Marinova, Georgi Mihaylov, Vladimir Maisnar, Maria-Victoria Mateos, Michael Wang, MD, Ruben Niesvizky, MD, Albert Oriol, Andrzej Jakubowiak, MD, PhD, Jiri Minarik, Antonio Palumbo, William Bensinger, MD, Vishal Kukreti, Dina Ben-Yehuda, Margaret Tonda, Mihaela Obreja and Philippe Moreau. Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
 18. Antonio Palumbo, Meletios A. Dimopoulos, Philippe Moreau, Wee-Joo Chng, Hartmut Goldschmidt, **Roman Hajek**, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD, Laura Rosinol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng and Douglas Joshua. Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According

to Age Subgroup. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018

19. Chiara Cerrato, Francesca Gay, Maria Teresa Petrucci, Pellegrino Musto, Gianluca Gaidano, Massimo Offidani, Tommasina Guglielmelli, Marco Salvini, Francesca Patriarca, Elena Ponticelli, Gianpietro Semenzato, Francesco Di Raimondo, Roberto Mina, Nicola Cascavilla, Dina Ben Yehuda, Daniela Oddolo, Paolo Corradini, Lucio Catalano, Paolo Di Bartolomeo, **Roman Hajek**, Andrew Spencer, Mario Boccadoro, MD and Antonio Palumbo. Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
20. Stuart D Russell, Alexander Lyon, Daniel J. Lenihan, MD, Philippe Moreau, Douglas Joshua, Wee-Joo Chng, Antonio Palumbo, Hartmut Goldschmidt, **Roman Hajek**, Thierry Facon, Heinz Ludwig, Ludek Pour, MD, Ruben Niesvizky, Albert Oriol, MD PhD, Laura Rosinol, MD PhD, Aleksandr Suvorov, Gianluca Gaidano, Vesselina Goranova-Marinova, Heidi H. Gillenwater, Nehal Mohamed, Shibao Feng and Meletios A. Dimopoulos. Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). 60TH ANNUAL MEETING & EXPOSITION OF THE AMERICAN SOCIETY OF HEMATOLOGY, San Diego, USA, 12/2018
21. Gumulec J., Kořístek Z., Šimetka O et al. Laboratorní diagnostika a diferenciální diagnostika u pacientů s podezřením na akutní ataku TMA. (abstrakt) TRANSFUZE HEMATOL. DNES 24, SUPPLEMENTUM 2/b; 2018, s. 127
22. Gumulec J., Šimetka O., Kaspřák D. et al. Soustředěná péče zlepšuje prognózu žen s těžkým HELLP syndromem a s postpartálním trombotickým mikroangiopatickým syndromem. (abstrakt) TRANSFUZE HEMATOL. DNES 24, SUPPLEMENTUM 2/b; 2018, s. 33-34
23. Gumulec J., Kaspřák D., Kořístek Z. et al. Soustředěná péče zvyšuje záchyt a zlepšuje prognózu pacientů s trombotickými mikroangiopatiemi. (abstrakt) TRANSFUZE HEMATOL. DNES 24, SUPPLEMENTUM 2/b; 2018, s. 99
24. Chng, WJ; Beksac, M; Hajek, R; Weisel, K; Mateos, MV; Spencer, A. Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM). JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):e20049
25. Costello, C; Boccadoro, M ; Usmani, SZ ; Chari, A ; Rifkin, RM ; Abonour, R ; Berdeja, J ; Cook, G ; Goldschmidt, H ; Hajek, R. et al. A Global Treatment Standard in Multiple Myeloma (MM) Remains Elusive Despite Advances in Care over 15 years: First Results from INSIGHT MM, the Largest Global Prospective, Observational MM Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2018;18:S247-S248.
26. Lonial, S ; Chng, WJ ; Beksac, M ; Hajek, R ; Weisel, K ; Mateos, MV ; Spencer, A ; Iida, S ; de Farias, D ; Labotka, R. Addressing Unmet Medical Needs in Maintenance Treatment for Newly Diagnosed Multiple Myeloma (NDMM). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2018;18:S248-S249.
27. Steiner, N ; Hajek, R ; Sevcikova, S ; Borjan, B ; Johrer, K ; Untergasser, G ; Gobel, G ; Gunsilius, E. Plasma levels of the angiogenic cytokine Endocan are elevated in patients with multiple myeloma. ONCOLOGY RESEARCH AND TREATMENT. 2018;41:192-193.
28. Steiner, N ; Hajek, R ; Muller, U ; Sevcikova, S ; Borjan, B ; Johrer, K ; Gobel, G ; Pircher, A ; Gunsilius, E. The metabolomic profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. ONCOLOGY RESEARCH AND TREATMENT. 2018;41:137-138.